ABSTRACT: Innate immune reactions to orthopedic implant debris are the primary cause of total joint replacement (TJR) failure over the long term (15-20 years). The role of pathogen associated pattern recognition receptors (i.e., TLRs) in regulating immune reactivity to metal implant particles remains controversial. Do different TLRs (i.e., TLR2 vs. TLR4) activated by their respective ligands in concert with metal implant debris elicit equivalent innate immune responses? In this investigation, our in vitro and in vivo data indicate that Gram-negative PAMPs are more pro-inflammatory than Gram-positive PAMPs. In vitro results indicated TLR4 activation in concert with CoCrMo orthopedic implant debris (CoCrMo/LPSþ) challenged primary macrophages resulted in significantly greater inflammatory responses than CoCrMo/PAM3CSKþ (TLR2). Similarly, in vivo results indicated CoCrMo/LPSþ TLR4 challenge induced a twofold increase in inflammation-induced bone resorption (osteolysis) than CoCrMo/ PAM3CSKþ (p < 0.01) or CoCrMo (p < 0.03) alone in an established murine calvaria model. This points to a more potent TLR4-based effect of CoCrMo/LPSþ on innate immune responses, that is, IL-1ß, TNF-a, and resulting osteolysis. Differential CoCrMo/LPSþ induced osteolysis compared to CoCrMo/PAM3CSKþ, reveals inherent differences in TLR4 versus TLR2 activation which are relevant to (i) how different types of implant debris elicit differential reactivity, (ii) how TLR2 Gram-positive bacteria benefits from less immune activation possibly due to the down-regulation of TLR2 surface expression, that subsequently impacts Gram-positive infections in TJRs, and (iii) how using TLR4 LPS (a Gram-negative agonist) may not accurately model Gram-positive bacteria responses, alone and/or with specific types of implant particles, particularly CoCrMo alloy. ß
It has been well established that implant debris causes local inflammation, limiting the long term performance of the over one million total joint replacements (TJR) implanted each year in the US. [1] [2] [3] Implant debris induces a subtle inflammatory cascade resulting in a slow progression of periprosthetic bone loss and/or attenuated osteointegration that over time (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) years) leads to implant failure. [1] [2] [3] This specific inflammatory response is attributed primarily to monocyte/ macrophage reactivity, where particles are phagocytosed by these lineage cells, resulting in their differentiation and activation. This activation subsequently leads to the upregulation of Danger Associated Molecular Pattern (DAMP) signaling and Pathogen Associated Molecular Pattern (PAMP) associated transcription factors, such as NFkB, 4 as well as the release of pro-inflammatory cytokines IL-1, TNF-a, IL-6, and IL-8. 5, 6 TLRs are conserved germline-encoded pattern recognition receptors (PRRs) that recognize invariant microbial structure (PAMPs), in which distinct PAMP moieties are generally recognized by particular TLRs. Prototypical PAMPs produced by Gram-positive (i.e., lipotechoic acid, LTA) and Gram-negative (i.e., lipopolysaccharide, LPS) bacteria are recognized by cell surface TLR2 and TLR4, respectively. 7 The role of TLRs in regulating immune reactivity to implant debris remains controversial. Previous studies have shown that both TLR2 and TLR4 agonists can potentiate the responses to implant debris and that are potential as therapeutic targets. [8] [9] [10] Macrophages in peri-prosthetic tissues express both TLRs abundantly. 11, 12 Mitigating implant debris immune reactivity through inhibition of PAMP signaling has been put forward as a means to combat debris induced aseptic osteolysis. 8, 9 However, the relative degree to which TLR2 versus TLR4-PAMP activation pathways can explicitly potentiate inflammatory immune reactivity to implant debris remains unknown and the distinction between these two TLR pathways is not trivial. It is unclear if specific pharmacologic blocking of one or both of these TLRs or their more central and common component(s) of PAMP pathway (i.e., NFkB) would be effective targets to mitigate implant debris induced inflammation. Sterile/endotoxin-free implant debris does not present the characteristic patterns of a typical pathogen and therefore do not directly activate TLRs. Previous evidence has shown PAMPs of TLR2 and TLR4, such as LTA and LPS respectively, can both adhere to particulate debris and increase inflammatory host response. 8 However, it remains unclear if TLR2 and/or TLR4 activation by their respective ligands in coordination with implant wear debris will elicit equivalent biologic activity/innate inflammatory immune response, and which, if either of these TLR ligands possesses a greater capability to exacerbate debris induced osteolysis. Gram-positive bacteria, for exaample, S. aureus (recognized by TLR2), account for approximately 65% of prosthetic joint infections compared to only 6% of infections caused by Gramnegative bacteria, for example, E. coli (recognized by TLR4). 13 A higher infection rate may require a more virulent specific response. Thus, we originally hypothesized that implant debris associated TLR2 activation will induce greater inflammation (IL-1b and TNF-a production) and subsequent inflammatory osteolysis when compared to TLR4 agonist of equal dose. We tested this in vitro by challenging a human monocyte/ macrophage cell line (THP-1) and primary human macrophages with equivalent doses of a PAM3CSK (a potent TLR2 ligand) or LPS (a potent TLR4 ligand), both with and without clinically relevant CoCrMo particulate debris, and measured IL-1b and TNF-a secretion. We additionally tested our hypothesis in vivo by measuring particle induced osteolysis in an established mouse calvaria model.
MATERIALS AND METHODS

Ethics Statement
This study and consent process received approval from the Rush University Institutional Review Board (10052606-IRB01-CR02). Participants provided their written consent to participate in this study. All participants were 18 years of age or older.
Animal Research C57BL/6 male mice (12 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, Maine) and kept under pathogen-free conditions. All experiments were carried out under the guidelines of the Institutional Animal Care and Use committee at Rush University Medical Center. The protocol was approved by the committee on the Ethics of Animal Experiments of Rush University Medical Center (IACUC Number: 13-065) and all in our study was conducted adhering to the institution's guidelines for animal husbandry, and followed the guidelines and basic principals in the Public Health Service Policy on Humane Care and Use of Laboratory Animals, and the Guide for the Care and Use of Laboratory Animals, United States Institute of Laboratory Animal Resources, National Research Council. All efforts were made to minimize suffering; all manipulations were performed under medetomidine/ketamine anesthesia and mice were sacrificed by cervical dislocation after anesthesia.
Media and Challenge Agents
Human monocyte cell line THP-1 (ATCC) were cultured with RPMI 1640 supplemented with L-Glutamine, Penicillin, Streptomycin, 25 mM Hepes (Lonza, Walkersville, MD) and 10% heat inactivated fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT). Human primary monocyte derived macrophages were cultured in RPMI 1640 supplemented with L-Glutamine, Penicillin, Streptomycin, 25 mM Hepes and 10% heat inactivated autologous serum.
PGN (TLR2 positive control), PAM3CSK (TLR2 positive control), and LPS (TLR4 positive control) (all purchased from Invivogen, San Diego, CA) were used in challenged monocytes/macrophages. The mean particle sizes of CoCrMo (CoCrMo, approximately 60%Co, 28%Cr, <6%Molybdenum, <1%Nickel, ASTM F75) particles were characterized by using low angle laser light scattering (LALLS) and Scanning Electron Microscopy (SEM). CoCrMo particles had a mean diameter of 0.88 mm diameter ECD (>95% less than 2 mm, >80% less than 1 mm, range 0.2-11mm diameter ECD, BioEngineering Solutions Inc., Oak Park, IL). This size of particulate debris has been shown to be clinically relevant and able to induce inflammatory responses in innate immune cells. 14, 15 Subsequent to characterization particles endotoxin cleaned using a three step process: (i) metal-safe detergent (Alconox), (ii) sonication in 70% ethanol for 1 h, followed by a 24 h 70% ethanol soak, and (iii) a 24 h soak in PyrocleanTM (a detergent for endotoxin removal). 16 Each step was followed by triple washing with deionized water (diH2O). Vacuum dried particles were autoclaved at the end of the cleansing process and tested to verify that they were endotoxin free using a quantitative limulus assay analysis, Kinetic QCL: <0.1eu (Pyrogent 5000, Lonza). Challenge concentrations were previously determined to be non-toxic after 24 h of challenge. 14, 17 THP-1 Cell Culture and Antibodies/Flow Cytometry Trypan Blue Stain exclusion method was performed to determine cell viability over 90% for all experiments and cells were subsequently plated. Human THP-1 monocytes (ATCC) were differentiated into macrophages by culturing 2.0 Â 10 5 monocytes/0.5 ml/well in triplicate in 48 well plates with phorbol ester (TPA 200 mM) for 24 h and then washed and rested for 24 h prior to challenge with 0, 1, 5, 50, 100, and 500 ng/ml of PGN (TLR2 positive control; Invivogen), PAM3CSK (TLR2 positive control; Invivogen), and LPS (TLR4 positive control; Invivogen) for 20 h at 37˚C 5% CO 2 in order to determine the optimal non-toxic dose and to compare the stimulatory effects of the various TLR ligands. Nondifferentiated THP-1 monocytes were cultured with 0.88 mm CoCrMo particles (5:1 ¼ particle: cell), LPS or PAM3CSK (100 ng/ml) for 20 h in triplicate in 48 well plates/0.5 ml/well. THP-1 cells were subsequently collected and 5 Â 10 5 cells were resuspended in FACs buffer and stained directly in flow tubes in 4˚C for 1 h with purified monoclonal FITC mouse anti-hTLR2 (5 ml), PE mouse anti-hTLR4 (5 ml) or APC mouse anti-human C1D14 antibody (5 ml) following manufacturer's instructions (each antibody was purchased from BD Biosciences) to detect monocytic surface expression of TLR2, TLR4, or CD14, respectively. PE Mouse IgG1 (5 ml; BD Biosciences) was used as an isotype control. Samples were subsequently washed and resuspended in 500 ml of FACs buffer and analyzed by flow cytometer. Flow cytometry was performed using a BD FACS Canto II instrument and the data were analyzed with FACS Diva software (BD Flow Cytometry Systems, San Jose, CA). A dual threshold for TLR expression was used for analysis to determine three ranges of TLR expression (i.e., negative, dim (mid-range), and bright (high)). These ranges were determined based on gating parameters determined from basal levels of TLR and CD14 expression in both negative and positive controls. 18 A single threshold was used for CD14 analysis.
PBMC Purification
Blood samples were obtained intravenously from healthy volunteers (n ¼ 5) under Rush University IRB-approved informed consent. Blood samples were obtained a total of three different appointments and 100 ml of blood was collected per blood draw/per person (three intervals over >3 months). Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized whole blood from donors by Ficol gradient separation. Human peripheral blood CD14þ monocytes were subsequently purified from the collected buffy coats (PBMCs fraction) using EasySep magnet according to the manufacturer's instructions for EasySep Human CD14 Positive Selection Kit (StemCell Technologies, Vancouver, Canada). Subsequently, isolated human primary monocytes (n ¼ 5) were differentiated into macrophages by culturing 2.0 Â 10 5 monocytes/0.5 ml/well in triplicate in 48 well plates with MCSF (50 ng/ml) for 24 h and then washed and rested for 24 h prior to metal CoCrMo challenge at a dose of 5:1 ¼ particles:cell (as determined previously to yield maximal inflammasome monocyte/macrophage responses 14, 17 ), and 100 ng/ml of LPS and PAM3CSK was used for in vitro PAMP challenge. Inflammatory monocyte/macrophage responses to the different TLR ligands were measured after 20 h of challenge at 37˚C 5% CO 2 . Supernatants were subsequently analyzed for mature IL-1b and TNF-a production.
ELISA Sandwich ELISAs for human IL-1b and TNF-a were used to detect challenged THP-1 macrophages and human primary monocyte derived macrophages (n ¼ 5) from triplicate from 48 well plates, using manufacturer's instructions (R&D Systems). Graphical data are shown as either the median concentration (þinterquartile range) or the mean concentration (þSEM) of cytokines of three independent experiments, each performed in triplicate.
Calvarial Osteolysis Model
All in vivo murine studies performed were approved by Rush University Institutional Animal Care Committee. Wild type male mice C57BL/6 were obtained from Jackson Laboratories (Bar Harbor, ME). 12 week old male C57BL/6 mice (n ¼ 30) were shaved prior to calvaria surgery, and the area was sterilized with 70% ethanol and iodine. Mice were then treated with one of six regimens (n ¼ 5 per group): (i) shamsurgery (sterile PBS;100 ml subcutaneously), (ii) 5 mg/ml PAM3CSK TLR2 agonist (100 ml subcutaneously), (iii) 5 mg/ ml LPS TLR4 agonist (100 ml subcutaneously), (iv) CoCrMo particles, (v) CoCrMo particles þ adherent 5 mg/ml PAM3CSK, and (vi) CoCrMo particles þ adherent 5 mg/ml LPS. Using a tailored protocol of Greenfield et al. 8 CoCrMo particles with adherent PAM3CSK or LPS (>10 Eu units/ 7 Â 10 8 particles per mouse, Kinetic QCL, Limulus assay) were produced by incubating endotoxin-free CoCrMo particles with 5 mg/ml PAM3CSK or highly purified 5 mg/ml LPS from E. coli (0111:B4) (both from InvivoGen, San Diego, CA) for 3 days in PBS. Particles were washed with PBS to remove non-adherent PAMPs. Each mouse calvaria was dosed with 2 mg CoCrMo particles (approximately 7 Â 10 8 particles) that was either endotoxin free or also contained adherent LPS or PAM3CSK (5ug/ml original stock concentration), by making a midline sagittal incision over the calvaria, exposing the intact periosteum. The concentration of LPS in vivo was based on clinically relevant septic levels in human plasma, where an endotoxin level <2 pg/ml is normal, 230 pg/ml indicates sepsis and >500 pg/ml indicates fatal sepsis. 19 The final dose of 5 mg/ml was chosen as an extreme challenge concentration where (i) the lack of response could not be due to low concentration dependent effects, (ii) represents locally worst case scenario, given local in vivo values of LPS contamination of implant debris has not been well characterized, and (iii) is 10-100 fold lower in concentration than those previously tested. 8 MicroCT and Osteolysis Analysis: 3D-CT was performed with an isometric resolution of 9 um. Areal osteolysis was determined at 10 days post-op by scanning isolated calvaria in a Scanco40 (ScanCoCrMoMedical, Basserdorf, Switzerland) transferred to an Amira 5.2 (TGS, Mercury Computer Systems, Inc., San Diego, CA) then image analyzed using ImageJ for % osteolysis (reported as the medians of n ¼ 5 mice per group with interquartile range of one individual experiment) within a circular control volume of approximately 1 cm located medially.
Tissue Histology
Wild-type calvaria were removed and fixed in 4% paraformaldehyde for 48 h, followed by decalcifying in 10% EDTA for 4 days and paraffin embedding. Sections (5 mm) were cut and H&E staining was performed. Photomicrographs were taken at an original magnification of Â100 or Â400.
Calvarial bone thickness as a measure of bone loss was quantified using four-micrometer thick sections of calvaria at the midsagittal suture proximal to the placement of particles. The sections were mounted on glass slides and subsequently HE staining was performed. HE-stained specimens were photographed digitally using a standard high-quality light microscope (Leica, Wetzlar, Germany). The image was oriented with the midline suture in the middle of the field. The sections were coded and blinded prior to analysis. Histomorphometric bone thickness measurements were performed using four equi-spaced measurements within the range of 750-1500 mm from the midline of midsagittal suture of the calvaria for each histology slide (n ¼ 5 per group, total of 20 measurements per group) (image analysis software Aperio ImageScope Version 11, LeicaTM, Wetzlar, Germany).
Statistical Analysis D'Agostino and Pearson omnibus normality test was performed to determine normality for each of the data sets. If the data set passed the normality test (a ¼ 0.05), then data were subsequently analyzed using Fisher's LSD for comparison of groups post-hoc after significance was determined with ANOVA, and is represented as the mean (þSEM) from triplicate data from three independent experiments. If the data set did not pass the criteria for the normality test (n ! 15), or was indeterminate due to the small number of data points (n < 15), then conservative comparative analysis for non-normal distributions was performed using MannWhitney for the comparison of two groups and KruskalWallis for the comparison of more than two data sets, which has less power to show significance than assumed parametric analysis (where data is graphically displayed with median and interquartile ranges). 20 All statistical analysis was performed using Prism 6.0 program (GraphPad, San Diego, CA). Statistical difference was considered significant at p 0.05.
RESULTS
TLR2 and TLR4 Agonists Induce THP-1 Macrophage Secretion of Both Pro-Inflammatory Cytokines IL-1b and TNF-a Dose response to each challenge agent was assessed using differentiated human THP-1 cell line (via TPA) with 0, 1, 5, 50, 100, and 500 ng/ml of PGN, PAM3CSK, and LPS. Both IL-1b and TNF-a secretion were measured at 20 h post exposure. All challenge agents induced concentration-dependent secretion of IL-1b and TNF-a in THP-1 cells (Fig. 1) . Although IL1b secretion increased with increasing concentrations PATHOGEN RECEPTOR DEPENDENT IMMUNE REACTIVITY TO IMPLANT PARTICLES of PAMP agonists, TLR2 ligand PAM3CSK induced maximal response at 5 ng/ml (2,625 pg/ml median secretion), whereas, TLR4 ligand LPS induced a relatively higher and maximal responses at 50 ng/ml (2,230 pg/ml median secretion; Fig. 1A) . Moreover, LPS and PAM3CSK challenge resulted in a similar increase in THP-1 macrophage secretion of IL-1b at all concentrations analyzed, with the exception of the 5 ng/ml (p ¼ 0.05; Fig. 1C) . The TNF-a production was the greatest in response to 500 ng/ml of LPS (7,482.52 pg/ml median secretion; Fig. 1B,D) , however, higher concentrations (>500 ng/ml) would be required to evaluate the peak response of TNF to LPS challenge. Induced secretion of TNF-a response to PAM3CSK challenge peaked at 50 ng/ml (5,954.08 pg/ ml median secretion) and was significantly different compared to LPS at both 1 ng/ml and 5 ng/ml (p 0.05) concentrations except at 50 ng/ml (p ¼ 0.1), 100 ng/ml (p ¼ 0.45), and 500 ng/ml (p ¼ 0.35; Fig. 1B,D) . In contrast to TLR2 PAM3CSK, TLR2 PGN derived from S. aureus was not as potent of an agonist as measured by increases in both IL-1b and TNF-a secretion (Fig. 1) . However, equal concentrations of PAM3CSK and LPS overall induced similar levels (non-significantly different) of IL-1b and TNF-a (only 100 and 500 ng/ml) in THP-1 cells (Fig. 1) . Due to the increased potency of PAM3CSK as a TLR2 agonist (over PGN), all further experiments conducted were performed with PAM3CSK versus TLR4 agonist LPS at the equal concentrations of 100 ng/ml. Fig. 2F ). There was no difference in monocyte basal levels of TLR2 versus TLR4 bright cells, that is, high expressing population (Fig. 2E) . However, after challenge with CoCrCo particles (20 h at a dose of 5:1 CoCrMo particles: cell) the basal expression of TLRs was altered by significantly increasing the amount of TLR4-negative cells (no TLR4 expression ¼ quadrant Q3-1-Q4-1) from 0.7% to 4% (p ¼ 0.05; Fig. 2G ). However, this response to Figure 2 . CoCrMo particle challenge significantly alters TLR2 and TLR4 surface expression on THP-1 monocytes. A representative flow graph from three independent experiments performed in triplicate showing the surface expression of (A) untreated TLR2þ cells, (B) TLR2þ cells after CoCrMo particle challenge, (C) untreated TLR4þ cells, and (D) TLR4þ cells after CoCrMo particle challenge. (E) Median values of TLR2 and TLR4 bright expression, (F) total TLR2 and TLR4 expression of control THP-1 cells, and (G) the percent increase in TLR negative (or dim) cells are shown both before and after challenge with CoCrMo particles. Note: High-TLR positive population or "bright" was based on top most quadrant % only and overall TLR expressing cells was determined from both middle and top quadrants. Negative-TLR population or "dim" was based on lower quadrants % only. Note:
Ã Represents p 0.05 compared to respective control treatment group as determined by Mann-Whitney following Kruskal-Wallis.
PATHOGEN RECEPTOR DEPENDENT IMMUNE REACTIVITY TO IMPLANT PARTICLES
CoCrMo particles was more complex than a simple increase in TLR4-negative population, given CoCrMo challenge also increased the percentage of THP-1 TLR4-bright cells, that is, those with high surface expression (i.e., increasing the % of TLR4 expressing cells from 2.1% to 4.75% after CoCrCo challenge, p ¼ 0.009; Fig. 2E ). CoCrMo particle challenge also induced a significant increase in TLR2-dim expression (dim/negative TLR2 expression ¼ quadrant Q3-Q4, 0.2% control versus 5.8%; p ¼ 0.05; Fig. 2G ). However, this reduction was not accompanied by a significant increase in TLR2-bright cells, unlike TLR4.
Both PAMP Agonists and CoCrMo Implant Particles Induce Human Primary Macrophages Secretion of Pro-Inflammatory
Cytokines IL-1b and TNF-a NLRP3 inflammasome dependent IL-1b, was significantly elevated in response to CoCrMo, CoCrMo/ PAM3CSKþ, CoCrMo/LPSþ, PAM3CSK, and LPS for 5/5 of individuals tested using primary monocyte derived macrophages (Fig. 3A) . IL-1b production was the greatest though in response to CoCrMo/LPSþ (876.8 pg/ml mean production and p < 0.0001 compared to negative control; Fig. 3A ,B) and LPS challenge (926.67 pg/ml mean production and p < 0.0001 compared to negative control; Fig. 3A,C) . CoCrMo/LPSþ co-challenge was significantly higher than both CoCrMo (610 pg/ml mean production; p < 0.002) and CoCrMo/PAM3CSKþ (640 pg/ml mean production and p < 0.04) for IL-1b. Similarly, CoCrMo/LPSþ co-challenge resulted in the greatest increase in TNF-a production (25,320 pg/ml mean production p < 0.001 compared to negative control; Fig. 3B,D) . TNF-a secretion to CoCrMo/LPSþ was also significantly greater compared to CoCrMo/PAM3CSKþ (15,805 pg/ml mean production, p ¼ 0.03) and to CoCrMo particles (19,300 pg/ml mean production; p ¼ 0.05). In contrast to the co-challenge of CoCrMo/LPSþ, CoCrMo/ PAM3CSKþ had similar production levels of IL-1b (p ¼ 0.2), but not TNF-a compared to CoCrMo challenge alone (p ¼ 0.02). When comparing the relative increase in IL-1b versus TNF, in response to CoCrMo/ LPSþ, TNF-a was highly increased with an approximately 10-fold greater increase compared to IL-1b (approximately 300Â vs. 30Â), Figure 3D versus C.
An In Vivo Murine Calvarial Model of Particle-Induced
Osteolysis Demonstrates CoCrMo Debris Co-Challenge With TLR4 Induces More Osteolysis Than TLR2 Co-Challenge Challenged mice with PAMP agonist alone, either TLR4 LPS (4.46% median osteolysis) or TLR2 PAM3CSK (6.10% median osteolysis), had minimal effect and exhibited non-significantly increased bone resorption compared to control (i.e., PBS only at 5.64% median osteolysis) WT mice (Fig. 4) . In contrast, CoCrMo particles, CoCrMo/PAM3CSKþ and CoCrMo/ LPSþ induced significantly greater bone resorption respectively at 16.41% (p ¼ 0.03), 16 .29% (p ¼ 0.008), and 26.02% (p ¼ 0.007), when compared to control group (Fig. 4) . Furthermore, CoCrMo/LPSþ induced the most bone loss with a 3.76-fold increase relative to the control, which was significantly greater compared to both CoCrMo (p < 0.03; fold increase 2.0 compared to control) and CoCrMo/PAM3CSKþ (p < 0.01; fold increase 2.0 compared to control; Fig. 4C ). Moreover, CoCrMo particle-induced osteolysis was statistically indistinguishable from the effects of CoCrMo/ PAM3CSKþ (i.e., approximately twofold greater osteolysis compared to controls; Fig. 4 ).
This microCT data were supported by qualitative histological evaluation (H&E staining) of the murine calvaria of tissue proximal to particle placement (Fig. 5) . Tissue histology demonstrated that CoCrMo particles alone, without residual LPS or PAM3CSK, are sufficient to elicit a potent osteolytic response due to invasion of the bone by inflammatory immune cells (Fig. 5 ). This analysis also showed how CoCrMo/LPSþ induced the most osteolysis as represented by the thickness of the remaining calvarial bone, where the average thickness was reduced to 42 mm (CoCrMo/ LPSþ) in comparison to untreated controls at 125 mm (p < 0.0001), CoCrMo at 70 mm (p < 0.05), and CoCrMo þ PAM3CSK at 82 mm (p < 0.03; Fig. 6 ).
DISCUSSION
Our in vitro and in vivo data refutes our original hypothesis, and alternatively indicates that CoCrMo implant particles in conjunction with TLR4 pathway activation via LPS, will result in disproportionately greater innate DAMP/PAMP inflammatory mediated responses (i.e., activation of NLRP3 inflammasome mediated IL-1b and NFkB mediated TNF-a) and resulting pathological bone resorption when compared to a potent TLR2 agonist PAM3CSK, at an equivalent dose. The activation of either CoCrMo particles alone or particles combined with PAMP agonists, demonstrated receptor specific signaling and pro-inflammatory responses; which provide insight into how Grampositive or Gram-negative bacteria present with metal implant debris can induce differential inflammatory innate immune responses that may mediate loosening of implants over the long term.
It has been recently recognized that similar pathomechanisms induce macrophage activation in both septic and aseptic TJR and resulting peri-implant osteolysis. 21 Although previous investigations have also demonstrated that both TLR2 and TLR4 PAMPs have the capability to aggravate this biological response of particulate debris. 8, 22 We tested the relative degree to which PAMP induced activation of TLR2 versus TLR4 could then respectively potentiate implant debris inflammasome mediated IL-1b and NFkB induced TNF-a production and subsequent osteolysis. We determined that this co-challenge and hence cosignaling varies depending on the specific PAMP agonist (i.e., TLR engaged); given that CoCrMo with LPS (CoCrMo/LPSþ), significantly augmented the innate inflammatory reaction and osteolytic response In vivo osteolysis using an established mouse calvaria model demonstrated that bone loss was significantly increased (additive effect) in response to CoCrMo with LPSþ, but not with PAM3CSKþ. However, an important limitation to this (and other similar studies), is that to date there is no effective way to measure adherent PAMPs on the particle surface directly (e.g., Limulus assays measure indirectly eluted amounts of LPS from surfaces), and thus PAMP-dependent effects shown here may be due to preferential PAMP-particle binding kinetics (i.e., retained/adherent PAMPs), with all else being equal. However, histological analysis of calvaria tissue proximal to particle challenge demonstrated that an inflammatory tissue pannus invading the bone causing osteolysis was apparent with both particles alone and when combined with PAMP agonists. The additive effect of CoCrMo and LPS on inflammatory bone PATHOGEN RECEPTOR DEPENDENT IMMUNE REACTIVITY TO IMPLANT PARTICLES resorption, suggests (at the least) a non-synergistic interaction of particle induced DAMP and LPS induced PAMP signaling. CoCrMo particles alone, without the addition of TLR agonists were able to significantly induce aseptic inflammatory osteolysis in vivo, whereas an equal dose of LPS or PAM3CSK challenge alone was not. This finding is consistent with the findings of others such as Greenfield et al. who reported high levels of adherent of TLR2 and TLR4 PAMPs to titanium particles increased their inflammatory responses less than additively when compared to PAMP stimulation alone, both in vitro and in vivo when examined only from the DAMP signaling perspective of NFkB dependent TNF-a production. 8 The current investigation is the first evaluation of the relative activation of the two major PAMP receptors TLR2 with PAM3CSK versus TLR4 with LPS at equivalent doses both alone and in concert with CoCrMo implant debris, and evaluated from both the DAMP (inflammasome produced IL-1b) and PAMP (NFk produced TNF-a secretion) perspective. Our in vitro data demonstrates that metal implant particles alone or combined with equivalent doses of Gramnegative TLR4 agonist LPS or with Gram-positive TLR2 agonist PAM3CSK, all induce an enhanced inflammatory response, but CoCrMo/LPSþ overall induced a more potent inflammasome mediated IL-1b and TNF response that trumped both CoCrMo and CoCrMo/PAM3CSKþ. Recent findings in innate immunity suggest the mechanics of how this occurs may be a result to differential control of human caspase-4/5 or the murine homologue caspase-11, that have been identified to directly recognize and be activated by cytoplasmic LPS, leading to non-canonical NLRP3 inflammasome activation. 23 This phenomena of co-Caspase (Caspase-11) dependent secretion of IL-1b has been reported for only LPS and not observed in response to PAM3CSK. 23 Previous investigations indicate that mRNA expression of TLR2 and TLR4 are inversely related, depend- ing on the specific PAMP agonist present with Tiparticles. [24] [25] [26] LPS-coated titanium particles, have been shown to decrease macrophage mRNA expression of TLR4 but not in response to LPS-free Ti particles, which had the opposite effect, increasing TLR4 mRNA expression up to 12 h after challenge. 24 This is consistent with the current investigation, which demonstrated increases in TLR4 cell surface expression to CoCrMo particle challenge. Others reported that Tiparticles (endotoxin free) resulted in down regulation of TLR4 mRNA, after 24 h in vitro stimulation in a mouse cell line, 26 demonstrating the importance of time of particle exposure/measurement. Conversely, mRNA of TLR2 has been shown to be up-regulated in response to Ti/LPSþ. 24 Another recent investigation showing different responses of TLR2 and TLR4 that also used Ti particles but with the TLR2 PAMP LTA, demonstrated a marked decrease of TLR2 but an increase of TLR4 mRNA expression. 25 Additionally, this phenomenon may be in part due to a shift in the cell population, as shown by our FACs analysis (Fig. 2) , that has significantly high TLR4 surface expression in response to CoCrMo. This may translate into more TLR4 receptor engagement and downstream signaling and activation via NFkB and NLRP3 inflammasome. In contrast, TLR2 expression was highly down-regulated (5.6% change in increased TLR2-dim expression versus 3.3% change in increased TLR4-dim expression induced by CoCrMo challenge respective to each control; Fig. 2G ), but this was not accompanied by a significant increase in a TLR2-high population after challenge with CoCrMo. However, despite the significant difference in the percentage of TLR2 versus TLR4-dim population (Fig. 2G ) when CoCrMo challenged (p ¼ 0.05), the relatively small percentage difference (vs. controls) may not be physiologically impactful. It has also been reported though that TLR2 is more promiscuous, that is, less specific than TLR4, in that it will form as a heterodimer upon stimulation with either TLR2/1 or TLR2/6 upon ligand binding. 27 Consequently, this may result in a more subdued role in non-pathogen specific innate immune responses since TLR2 requires more regulation to initiate and control a proper immune response. 26 Another possible explanation for the relatively muted role of TLR2 may be due to a greater dependence on coupled DAMP signaling for an effective immune response, as supported by reports of Gram-positive S. aureus inhibiting DAMP signaling (through ameliorated lysozyme disruption and thus degraded phagocy- ). Therefore, the observed lack of an increase in inflammation and bone loss by TLR2 agonist PAM3CSK with CoCrMo, as well as decreased surface expression of TLR2 (i.e., decrease in cell signaling), may possibly be due to an evolutionary advantage generated of Gram-positive bacteria that translates into decreased immune reactivity and enhanced bacterial survival. 28 This explanation is further supported by the use of PGN derived from S. aureus, that was not as potent a TLR2 agonist compared PAM3CSK and thus not equivalently inflammatory as TLR4 LPS, as measured by cytokine secretion of both IL-1b and TNFa. In contrast to TLR2 agonists, TLR4 activators may elicit a more potent immune response because TLR4 receptors have been shown to activate both NFk dependent (early phase) and independent (late phase, for example, IFN cytokines 29 ) immune reactivity. Thus, TLR4 may preferentially to TLR2 induce extra/complimentary intracellular pathways of inflammation with inflammasome danger signaling. Previous reports have shown other cytokines may also be involved and exacerbate inflammatory responses, for example, IFN-gamma has been shown to augment human monocyte/macrophage inflammatory response (specifically IL-6 and TNF-a) to PMMA particle challenge 30 which may also play central roles in the degree of reactivity to CoCrMo/LPSþ challenge but has yet to be investigated.
Therefore, TLR2 versus TLR4 in concert with implant debris may be essentially distinct pathways, in the context of clinical approaches to mitigate them effectively. Investigations of implant debris should accordingly treat TLR2 and TLR4 PAMPs interactions with orthopedic implant debris as separate, where one type of TLR activation may not be used as a proxy of another. This is supported by well established clinical data, where Gram-positive bacteria, for example, S. aureus (recognized by TLR2), account for approximately 65% of prosthetic joint infections compared to only 6% of infections caused by Gram-negative bacteria, for example, E. coli (recognized by TLR4). 13 This is an exaggeration of the general non-implant related picture infection where it has been reported that in the United States, 52% of sepsis cases are due to Gram-positive organisms, while 38% of cases resulted from Gram-negative bacteria. 27 This demonstrates strong differences in how TLR signaling can preferentially react to and presumably act to help clear Gramnegative bacteria as opposed to Gram-positive bacteria (e.g., S. aureus). Thus, TLR reactivity differences may be one of many ways (e.g., biofilm formation, virulence factors, etc.) that Gram-positive bacteria exploit immune reactivity relative to Gram-negative bacteria.
Further study is needed to build consensus and investigate how TLR and inflammasome interactions govern immune reactivity to metal, ceramic and polymeric implant debris. As well, additional investigation is required to determine direct versus indirect TLR activation dependence on particle size and implant debris type (e.g., soluble ions vs. particles). Moreover, while it has been reported that healthy human monocytes express relatively similar high surface levels of TLR2 and TLR4, 31 further analysis of TLRs expression and regulation is required of human cells to fully understand the extent to which different types of orthopedic implant debris can modulate their expression. Another limitation of this current study, is a the relatively short term in vivo murine particle-induced osteolysis model used to approximate the reactivity of implant debris over the long term. Further analysis is also required to more fully characterize the number and frequency of macrophage subset/activity using identifying surface markers of the infiltrating immune cells observed in murine tissue. Efforts are underway to analyze the signaling mechanism(s) involved in inflammatory osteolysis due to distinct PAMP stimuli in vivo, and evaluate the role of murine caspase-11 and human caspase-4/5 activation by LPS versus PAM3CSK with implant debris.
In summary, our in vitro and in vivo data provide evidence that distinct PAMPs of TLR2 or TLR4 at equivalent doses in concert with CoCrMo particulate implant debris will result in differential innate inflammation, where the TLR4 agonist LPS combined with CoCrMo particles preferentially induces a more extreme IL-1b and TNF-a inflammatory response and greater inflammatory osteolysis (vs. CoCrMo or CoCrMo/PAM3CSKþ). The different responses reported here provide insight that may account (in part) for biologic reactivity differences and aggravated osteolysis in TJA patients with subclinical levels of Gram-positive versus Gram-negative bacteria. 
